Interstitial lung diseases (ILDs) represent a diverse group of more than 200 lung disorders characterized by inflammation and fibrosis of the lung interstitium. This article aims to provide healthcare professionals with a comprehensive understanding of ILDs, their diagnosis, and treatment options.
ILDs can be idiopathic or secondary to systemic diseases, occupational and environmental exposures, or drug toxicity. The pathogenesis typically involves damage to the lung interstitium, leading to an aberrant repair response, inflammation, fibrosis, and ultimately, loss of lung function.
Patients with ILDs often present with non-specific symptoms such as dyspnea, cough, and fatigue. High-resolution computed tomography (HRCT) is the cornerstone of ILD diagnosis. Pulmonary function tests, bronchoalveolar lavage, and lung biopsy may also be used for diagnosis and to assess disease severity.
Management strategies for ILDs are multifaceted and depend on the underlying cause. In idiopathic cases, treatment is largely supportive, including supplemental oxygen and pulmonary rehabilitation. Pharmacological therapies, such as corticosteroids and immunosuppressants, are used in cases of inflammatory ILDs. Antifibrotic agents are increasingly used in managing fibrotic ILDs. Lung transplantation remains a last resort for patients with advanced disease.
Given the complexity of ILDs, a multidisciplinary approach is essential for optimal patient management. This approach includes pulmonologists, radiologists, pathologists, rheumatologists, and patient support groups. This collaborative approach ensures comprehensive patient care and improves outcomes.
Interstitial lung diseases are complex disorders requiring a thorough understanding for effective management. As healthcare professionals, staying updated on the latest diagnostic and therapeutic advances is crucial to provide the best possible care for patients with ILDs.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation